ArticleThe Indian journal of medical research2021
Evaluation of bacteriophage cocktail on septicaemia caused by colistin-resistant
Article in The Indian journal of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Bacteriophage research in India and its implications for human health: A scoping review.The Indian journal of medical research · 2026Article
- Bacteriophages targetingFrontiers in microbiology · 2026Review
- CombatingFrontiers in cellular and infection microbiology · 2025Review
- A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.Molecular biology reports · 2024Review
- Review
- Phage-encoded depolymerases as a strategy for combating multidrug-resistantFrontiers in cellular and infection microbiology · 2024Review
- Bacteriophages and their derived enzymes as promising alternatives for the treatment of Acinetobacter baumannii infections.Archives of virology · 2023Review
- Review
- Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens.Frontiers in medicine · 2023Review
- Recent Advances in Phage-Based Therapeutics for Multi-Drug ResistantBioengineering (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & objectives: Since the bacterium, Acinetobacter baumannii (AB) has acquired resistance to almost all commercially available antibiotics, the search for alternative treatment options continues to be need of the hour. Bacteriophage therapy seems to be the most promising amongst various proposed alternatives (e.g. antimicrobial peptides, bacteriocin, probiotics, etc.). The present study, therefore, aimed to evaluate the effect of different dosages of specific phages in immunocompromised rodents in a septicaemia model caused by AB mimicking real clinical situations. Methods: The three most active and unique phages (ɸAb4, ɸAb7 and ɸAb14) were selected for this study. A constant dose (100 μl of 10 Results: The administration of 100 μl (10 Interpretation & conclusions: As per the results of this study, it may be concluded that even if patients with acute infections report late to the hospital, a relatively low dose of the phage cocktail may be therapeutically beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.